Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Alto Neuroscience (NYSE:ANRO) had its price target upped by equities researchers at Robert W. Baird from $22.00 to $41.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price target suggests a potential upside of 82.17% from the company’s current price.

A number of other equities analysts also recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a report on Monday. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Tuesday. BTIG Research boosted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Finally, Wedbush upped their target price on Alto Neuroscience from $13.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.33.

Alto Neuroscience Stock Down 7.3%

Shares of NYSE:ANRO opened at $22.51 on Wednesday. The stock has a 50-day simple moving average of $18.11 and a 200-day simple moving average of $13.35. The stock has a market capitalization of $699.29 million, a P/E ratio of -10.32 and a beta of 2.52. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $25.17. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.11. Equities analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. acquired a new position in Alto Neuroscience in the 1st quarter worth $67,000. AQR Capital Management LLC purchased a new stake in shares of Alto Neuroscience during the first quarter worth about $52,000. Bank of Montreal Can acquired a new position in shares of Alto Neuroscience in the second quarter worth about $25,000. AlphaCore Capital LLC boosted its holdings in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after purchasing an additional 84,417 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.